An overview of candesartan in clinical practice

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 8, 2011, Pages 975-982

  Khawaja, Zeeshan ^a   Wilcox, Christopher S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

candesartan; heart failure; hypertension

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; NATEGLINIDE; NIFEDIPINE; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

ALBUMINURIA; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MONOTHERAPY; MORTALITY; PREHYPERTENSION; RECEPTOR BINDING; RETINOPATHY; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; PREHYPERTENSION; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES;

EID: 80052485105     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.90     Document Type: Review

References (56)

1. Chobanian AV, Bakris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289, 2560-2572 (2003).
2. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J. Hypertens. 25, 1105-1187 (2007).
3. Weber M. Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes? Eur. Heart J. 5(Suppl. C), C1-C4 (2003).
4. Waeber B. Combination therapy with ACE inhibitors/angiotensinII receptor antagonists and diuretics in hypertension. Expert Rev. Cardiovasc. Ther. 1(1), 43-50 (2003).
5. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122, 290-230 (2009).
6. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE), a randomized, parallel-group trial. Lancet 377(9762), 312-320 (2011).
7. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The cycle repeats. Drugs 62, 443-462 (2002).
8. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am. J. Med. 116, 30S-38S (2004).
9. Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), a multicentre randomized controlled trial. Lancet 366, 895-906 (2005).
10. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am. J. Hypertens. 13(1 Pt 2), 18S-24S (2000).
11. Vanderheyden PML, Fierens FLP, Vauquelin G. Angiotensin II type 1receptor antagonists. Why do some of them produce insurmountable inhibition? Biochem. Pharmacol. 60, 1557 (2000).
12. Vauquelin G, Fierens FLP, Vanderheyden PML. Distinction between surmountable and insurmountable angiotensin II AT1 receptor antagonists. In:Angiotensin II Receptor Antagonists. Epstein M, Brunner HR, (Eds). Hanley and Belful, PA, USA, 105-118 (2000).
13. Gleiter CH, Mörike K. Clinical pharmacokinetics of candesartan. Clin. Pharmacokinet. 41, 7-17 (2002).
14. Van Liefde I, Vauquelin G. Sartan AT (1) receptor interaction: in vitro evidence for insurmountable antagonism and inverse agonsim. Mol. Cell Endocrinol. 302(2), 237-243 (2009).
15. Sever P, Michel J, Voet B. Candesartan cilexitil (CC), A meta-analysis of time-to-effect relationship. Am. J. Hypertens. 11(4 Pt 2), 79A (1998).
16. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press. 11(5), 293-301 (2002).
17. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A, Redon J, Asmar R, Hedner T. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press. 10(1), 43-51 (2001).
18. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J. Hum. Hypertens. 11(Suppl. 2), S63-S64 (1997).
19. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/ losartan study investigators. Am. J. Hypertens. 12(12 Pt 1-2), 1181-1187 (1999).
20. Bönner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr. Med. Res. Opin. 20(5), 597-602 (2004).
21. Azizi M, Nisse-Durgeat S, French Collaborative Group. Comparison of the antihypertensive effects of the candesartan 8 mg hydrochlorothiazide 125 mg combination vs. the valsartan 80 mg hydrochlorothiazide 125 mg combination in patients with essential hypertension resistant to monotherapy. [Abstract no. P2367]. J. Hypertens. 22(Suppl. 2), S254-S255 (2004).
22. Uen S, Un I, Fimmers R, Vetter H, Mengden T. Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension. Deutsche Medizinische Wochenschrift 132(3), 81-86 (2007).
23. Edes I. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin. Drug Investig. 29(5), 293-304 (2009).
24. Oparil S, Michelson EL. Long term efficacy, safety, and tolerability of candesartan cilexitil added to hydrochlorothiazide in patients with severe hypertension. Am. J. Hypertens. 12, 120 (2009).
25. Bramlage P, Schonrock E, Odoj P, Wolf WP, Funken C. Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ. MMW Fortschritte der Medizin. 149(Suppl. 4), 172-181 (2008).
26. Bönner G. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/125 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press. 17(Suppl. 2), 22-30 (2008).
27. Hasebe N, Kikuchi K; NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J. Hypertens. 23(2), 445-453 (2005).
28. Papadopolous D, Makris T, Papademtriou V. Is it time to treat prehypertension? Hypertens Res. 31(9), 1681-1686 (2008).
29. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 354, 1685-1697 (2006).
30. Egan B, Nesbitt S, Julius S. Prehypertension: should we be treating with pharmacologic therapy? Ther. Adv. Cardiovasc. Dis. 2(4), 305-314 (2008).
31. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet 362(9386), 759-766 (2003).
32. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362(9386), 767-771 (2003).
33. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386), 772-776 (2003).
34. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362(9386), 777-781 (2003).
35. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008, the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29(19), 2388-2442 (2008).
36. Lithell P, Hansson L, Skoog I et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE), principal results of a randomized double-blind intervention trial. J. Hypertens. 21(5), 875-886 (2003).
37. Papademetriou V, Farsang C, Elmfeldt D et al.; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll Cardiol. 44(6), 1175-1180 (2004).
38. Schrader J, Luders S, Kuschewski A et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34(7), 1699-1703 (2003).
39. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359(12), 1225-1237 (2008).
40. Sandset EC, Bath PM, Boysen G et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST), a randomised, placebo-controlled, double-blind trial. Lancet 377(9767), 741-750 (2011).
41. Lam SK, Owen A. Incident diabetes in clinical trials of antihypertensive drugs. Lancet 369(9572), 1513-1514 (2007).
42. Jandeleit-Dahm K, Tikellis C, Reid C et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 23(3), 463-473 (2005).
43. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. 21(8), 1563-1574 (2003).
44. Preiss D, Zetterstrand S, McMurray JJ et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 32(5), 915-920 (2009).
45. Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201-207 (2007).
46. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension 51, 393-398 (2008).
47. Yusuf S, Ostergreb J, Gerstein H et al.; Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112(1), 48-53 (2005).
48. Bosh J, Yusuf S, Gerdtein H et al.; DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355(15), 1551-1562 (2006).
49. McMurray JJ, Holman RR, Haffner SM et al.; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362(16), 1477-90 (2010).
50. Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann. Intern. Med. 151(1), 11-20 (2009).
51. Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in Type 2 diabetes (DIRECT-Protect 2), a randomised placebo-controlled trial. Lancet 372(9647), 1385-1393 (2008).
52. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in Type 1 diabetes: randomised, placebo-controlled trials. Lancet 372(9647), 1394-1402 (2008).
53. Fogari R, Mugellini A, Derosa G; CANDIA (Candesartan and Diuretic vs Amlodipine in Hypertensive Patients) Study Group. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. J. Renin Angiotensin Aldosterone Syst. 8(3), 139-144 (2007).
54. Oparil S. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. Am. J. Cardiol. 84(10A), 35S-41S (1999).
55. Mogensen C, Neldam S, Tikkanen I et al. Randomized controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. 321, 1440-1444 (2000).
56. Kincaid-Smith P, Fairley K, Packham D et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638), 547-553 (2008).